Lipid core nanoparticles resembling low-density lipoprotein and regression of atherosclerotic lesions: effects of particle size

Imagem de Miniatura
Arquivos
art_FREITAS_Lipid_core_nanoparticles_resembling_lowdensity_lipoprotein_and_regression_2018.PDF (1.33 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.51, n.3, article ID e7090, 8p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Particles are usually polydispersed and size is an important feature for lipid-based drug delivery systems in order to optimize cell-particle interactions as to pharmacologic action and toxicity. Lipid nanoparticles (LDE) with composition similar to that of low-density lipoprotein carrying paclitaxel were shown to markedly reduce atherosclerosis lesions induced in rabbits by cholesterol feeding. The aim of this study was to test whether two LDE fractions, one with small (20-60 nm) and the other with large (60-100 nm) particles, had different actions on the atherosclerotic lesions. The two LDE-paclitaxel fractions, prepared by microfluidization, were separated by density gradient ultracentrifugation and injected (4 mg/body weight, intravenously once a week) into two groups of rabbits previously fed cholesterol for 4 weeks. A group of cholesterol-fed animals injected with saline solution was used as control to assess lesion reduction with treatment. After the treatment period, the animals were euthanized for analysis. After treatment, both the small and large nanoparticle preparations of LDE-paclitaxel had equally strong anti-atherosclerosis action. Both reduced lesion extension in the aorta by roughly 50%, decreased the intima width by 75% and the macrophage presence in the intima by 50%. The two preparations also showed similar toxicity profile. In conclusion, within the 20-100 nm range, size is apparently not an important feature regarding the LDE nanoparticle system and perhaps other solid lipid-based systems.
Palavras-chave
Solid lipid nanoparticles, Drug targeting, Paclitaxel, Atherosclerosis, Particle size
URI
https://observatorio.fm.usp.br/handle/OPI/26287
Referências
  1. Ades A, 2001, GYNECOL ONCOL, V82, P84, DOI 10.1006/gyno.2001.6203
  2. Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015
  3. Boverhof DR, 2015, REGUL TOXICOL PHARM, V73, P137, DOI 10.1016/j.yrtph.2015.06.001
  4. Bulgarelli A, 2012, J CARDIOVASC PHARM, V59, P308, DOI 10.1097/FJC.0b013e318241c385
  5. Champion JA, 2008, PHARM RES-DORDR, V25, P1815, DOI 10.1007/s11095-008-9562-y
  6. Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3
  7. Dorlhiac-Llacer PE, 2001, BRAZ J MED BIOL RES, V34, P1257, DOI 10.1590/S0100-879X2001001000004
  8. Feng L, 2013, CANCER LETT, V334, P157, DOI 10.1016/j.canlet.2012.07.006
  9. Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564
  10. Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654
  11. He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
  12. Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y
  13. Jiang LQ, 2017, INT J NANOMED, V12, P6383, DOI 10.2147/IJN.S142060
  14. Kathe N, 2014, DRUG DEV IND PHARM, V40, P1565, DOI 10.3109/03639045.2014.909840
  15. Kelly C, 2011, J DRUG DELIV, DOI 10.1155/2011/727241
  16. Kretzer IF, 2016, INT J NANOMED, V11, P885, DOI 10.2147/IJN.S88546
  17. Lameijer MA, 2013, EXPERT REV MOL DIAGN, V13, P567, DOI 10.1586/14737159.2013.819216
  18. Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051
  19. Maranhao RC, 2015, EXPERT OPIN DRUG DEL, V12, P1135, DOI 10.1517/17425247.2015.999663
  20. MARANHAO RC, 1994, CANCER RES, V54, P4660
  21. Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3
  22. Mendes S, 2009, GYNECOL ONCOL, V112, P400, DOI 10.1016/j.ygyno.2008.10.018
  23. Moura JA, 2011, INT J NANOMED, V6, P2285, DOI 10.2147/IJN.S18039
  24. Namdee K, 2014, ATHEROSCLEROSIS, V237, P279, DOI 10.1016/j.atherosclerosis.2014.09.025
  25. Naoum FA, 2004, AM J HEMATOL, V77, P340, DOI 10.1002/ajh.20206
  26. Occhiutto Marcelo L, 2012, Pharmaceutics, V4, P252, DOI 10.3390/pharmaceutics4020252
  27. Palombo M, 2014, ANNU REV PHARMACOL, V54, P581, DOI 10.1146/annurev-pharmtox-010611-134615
  28. Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8
  29. Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2
  30. Psarros C, 2012, NANOMED-NANOTECHNOL, V8, pS59, DOI 10.1016/j.nano.2012.05.006
  31. REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1
  32. Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y
  33. Rodrigues DG, 2002, J PHARM PHARMACOL, V54, P765, DOI 10.1211/0022357021779104
  34. Sacks FM, 2015, CURR OPIN LIPIDOL, V26, P56, DOI 10.1097/MOL.0000000000000146
  35. Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
  36. Setyawati MI, 2015, CHEM SOC REV, V44, P8174, DOI 10.1039/c5cs00499c
  37. Teixeira RS, 2004, J PHARM PHARMACOL, V56, P909, DOI 10.1211/0022357023826
  38. Valduga CJ, 2003, J PHARM PHARMACOL, V55, P1615, DOI 10.1211/0022357022232
  39. Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31